Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma

NCT06803875 is registered in ClinicalTrials.gov with Roberto Chiarle as lead sponsor.

NCT NCT06803875
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06803875 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma
Lead sponsor
Roberto Chiarle
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 31, 2025
Completion date
December 31, 2029
Enrollment
42 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

high-risk neuroblastoma, refractory neuroblastoma, relapsed neuroblastoma